Information about Zyclara (Imiquimod)
Zyclara is a topical medication that contains Imiquimod, an immune response modifier that works by stimulating the immune system to fight against abnormal skin cells. Zyclara is primarily used for treating certain skin conditions, such as actinic keratosis, superficial basal cell carcinoma, and genital warts caused by the human papillomavirus (HPV). It is applied directly to the affected area to help the body’s immune system combat the abnormal growth of cells.
Product Highlights
- Zyclara (Imiquimod) is primarily prescribed for the treatment of:
- Zyclara is used to treat this precancerous skin condition, which may develop into squamous cell carcinoma if left untreated.
- This medication can help treat certain types of skin cancer when surgery is not an option or is not preferred.
- Zyclara is also used to treat external genital warts caused by human papillomavirus (HPV) in adults.
Key Ingredient
Key Benefits
- Zyclara is effective in treating actinic keratosis, superficial basal cell carcinoma, and genital warts by stimulating the body’s immune system to target and destroy abnormal skin cells and wart-causing viruses.
- As a topical cream, Zyclara offers a non-invasive treatment option, which is ideal for patients who prefer to avoid surgical procedures or other more aggressive treatments.
- Zyclara is applied directly to the skin in the affected areas, allowing for localized treatment without systemic side effects.
Direction of Use
- Apply Zyclara cream directly to the affected area, usually once daily before bedtime, for the duration recommended by your doctor. The typical treatment duration varies:
- Actinic Keratosis: Applied 3 times a week for 16 weeks.
- Genital Warts: Applied once daily, 5 days a week for up to 16 weeks, or until the warts resolve.
- Gently cleanse and pat the affected area dry before applying the cream.
- Use a thin layer of the cream, covering the affected skin without excessive application.
- Do not apply Zyclara to the eyes, inside the nose, mouth, or genital area unless specifically directed by a healthcare provider.
- After applying Zyclara, wash your hands thoroughly to avoid spreading the medication to other areas or people.
- During treatment, avoid excessive sun exposure as the skin may become more sensitive to sunlight.
Safety Concerns
- Common side effects include redness, irritation, swelling, peeling, and itching at the application site. These side effects are generally short-lived and resolve once treatment is completed. Less common side effects may include flu-like symptoms, fever, or headaches.
- Zyclara can cause skin reactions, which may range from mild irritation to more severe redness or blistering. These reactions generally improve after the treatment is discontinued.
- Although rare, some patients may experience systemic side effects, especially if the cream is used over large areas of the body or for extended periods.
- Zyclara should be used during pregnancy only if clearly needed and prescribed by a healthcare provider. It is not known if imiquimod passes into breast milk, so breastfeeding mothers should consult their doctor before use.
- Treatment with Zyclara may make the skin more sensitive to sunlight, increasing the risk of sunburn. Avoid sun exposure and use sunscreen during the treatment period.
Avoid Zyclara (Imiquimod) If
- You are allergic to Imiquimod or any of the ingredients in Zyclara.
- You have open sores or broken skin at the treatment site, as it may cause further irritation.
- You are pregnant, planning to become pregnant, or breastfeeding, unless specifically advised by a healthcare provider.
- You have a history of severe skin reactions to topical medications or immune-modifying drugs.
- You have any known allergies to components in the cream, such as benzyl alcohol or other excipients.
